Video

Managing Hypertension and Thyroid Cancer

Author(s):

Lori J. Wirth, M.D.

High blood pressure is common in patients with thyroid cancer who are taking Lenvima. Here's what one expert says about managing it.

The majority of patients with iodine-refractory, differentiated thyroid cancer end up developing high blood pressure (hypertension) as a result of treatment with Lenvima (lenvatinib), according to Lori J. Wirth, M.D., associate professor of Medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital.

If a patient develops hypertension during treatment, the medical team should not stop treatment, but instead find ways to manage the hypertension. This can include giving the patient blood pressure medications or stopping Lenvima for a period of time, but then re-administering the agent.

Related Videos
Image of a woman with long red hair.
Image of a man in a suit.
Image of woman with brown hair.
Image of a man with short hair, wearing a buttoned-up shirt.
Image of a man with short black hair.
Image of a woman with tied back hair, wearing pearl earrings.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a man with short black hair.
Image of man with gray hair.
Related Content
Two illustrations of people with tumors in the throat and jaw area.
October 19th 2024

Similar Survival Shown With Radiation Versus Robotic Surgery in HNC

Ashley Chan
Patients with a head and neck cancer subtype did not show differences in survival outcomes when treated with radiation versus transoral robotic surgery.
An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer
November 6th 2023

An Update on the Cancer Drug Shortage, FDA Approvals and Cervical Cancer

Alex Biese Brielle Benyon
CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.
A Keytruda-based regimen given both before and after surgery for patients with head and neck squamous cell carcinoma may improve event-free survival.
October 15th 2024

Keytruda Regimen May Improve Event-Free Survival in Head and Neck Squamous Cell Carcinoma

Darlene Dobkowski, MA
A Keytruda-based regimen given both before and after surgery for patients with head and neck squamous cell carcinoma may improve event-free survival.
Bill C. Potts holding his small dog, Pippa | Photo credit: Sarah Potts
August 10th 2023

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

Ashley Chan
Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”
FDA text.
October 1st 2024

Oncology Drugs Approved by the FDA in September 2024

Darlene Dobkowski, MA
Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid cancer and breast cancer.
Image of a vial of treatment and a syringe with "out of stock," signifying the chemo shortage.
September 30th 2024

Chemo Shortage Increases Treatment Costs by 16% for Head and Neck Cancer

Darlene Dobkowski, MA
In addition to increased treatment costs, patients with head and neck cancers also experienced therapy changes during the cisplatin shortage.